Pegaspargase - Polaris PharmaceuticalsAlternative Names: ASNase-PEG - Polaris Pharmaceuticals; PEG-asparaginase - Polaris Pharmaceuticals
Latest Information Update: 06 Jan 2017
At a glance
- Originator Polaris Pharmaceuticals
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Jan 2017 Early research in Cancer in USA (Parenteral)